Eli Lilly and Company

Other

Elan Pharmaceuticals, Inc.

Intermune, Inc.

Athena Neurosciences, Inc.

Richard Craig Thompson

Stephen Charles Wilkie

James E Audia

Warren Jaye Porter

Douglas Richard Stack

Thomas Charles Britton

Qing Shi

Richard Duane Johnston

Mark J Zweifel

Michael J Rodriguez

Robin D Cooper

Nancy June Snyder

Nathan Bryan Mantlo

Bret E Huff

Michael A Staszak

Thalia I Nicas

John T Quatroche

Jon Kevin Reel

Thomas Edward Mabry

Lee H Latimer

Bruce Anthony Dressman

Yanping Xu

Russell Dean Stucky

Steven Scott Henry

Stacey L McDaniel

George W Huffman

Cynthia L Cwi

Xiaodong Wang

Eldon E Vanmeter

Jeffrey S Nissen

Jay S Tung

Philip Arthur Hipskind

Leonard Larry Winneroski, Jr

Samuel James Dominianni

Erik James Hembre, Ii

Jianliang Lu

Chafiq Hamdouchi

Daniel Ray Mayhugh

Takako Takakuwa

Ashraf Saeed

Christopher Randall Schmid

Paul Andrew Hyslop

Michael John Rupp

Elizabeth Aaron Collins

Laura I Tanner

Heather Janelle Barbosa

Tracey Ann Gibson

Garret Jay Etgen

The present invention relates to novel substituted imidazo[1,2-b]pyridazine compounds of Formula (I): pharmaceutical compositions thereof, and the use such compounds as corticotropin releasing factor 1 (CRF1) receptor antagonists in the treatment of psychiatric disorders and neurological diseases. 

Imidazopyridazine compounds

The present invention is directed to compounds represented by the following structural Formula (I), (a) R1 is selected from the group consisting of hydrogen, substituted or unsubstituted group selected from C-Calkyl, aryl-C-alkyl, heteroaryl-C-alkyl, C-Ccycloalkylaryl-C-alkyl, and &#x2014;CH&#x2014;C(O)&#x2014;R17-R18, wherein R17 is O or NH and R18 is optionally substituted benzyl; (b) R2 is selected from the group consisting of C-Calkyl, C-Calkenyl, aryl-C-alkyl, heteroaryl-C-alkyl, C-Calkyl sulfonamide, C-Calkyl amide, OR10 and C-Ccycloalkyl; (c) W is O or S; (d) X is an optionally substituted C-Calkylene linker wherein one carbon atom of the linker may optionally be replaced with O, NH, S, and optionally two carbons together may form a double bond; (e) Y is selected from the group consisting of C, O, S, NH and a single bond; and (f) E is selected from the group consisting of C(R3)(R4)A, A, and a substituted or unsubstituted group selected from the group consisting of (CH)n COOR19. 

Peroxisome proliferator activated receptor agonists

The present invention provides a process for selectively acylating an A82846A, A82846B, A82846C or PA-42867-A glycopeptide at the N1, N2 or N3 positions and the monoacylated compounds prepared therefrom.

Selective N-acylation of A82846 glygopeptides analogs

The present invention is directed to compounds represented by the following structural formula, and pharmaceutically acceptable salts, solvates and hydrates thereof, R1 is a substituted or unsubstituted group selected from C-Calkyl, aryl-C-alkyl, heteroaryl-C-alkyl, C-Ccycloalkylaryl-C-alkyl or phenyl. W is O or S. R2 is H or a substituted or unsubstituted group selected from C-Calkyl, C-Ccycloalkyl and heteroaryl. X is a C-Calkylene linker wherein one carbon atom of the linker may be replaced with O, NH or S. Y is C, O, S, NH or a single bond. Furthermore, E is (CH)COOH, wherein n is 0, 1, 2 or 3, or C(R3)(R4)A, wherein A is an acidic functional group such as carboxyl, carboxamide substituted or unsubstituted sulfonamide, or substituted or unsubstituted tetrazole. R3 is H, saturated or unsaturated C-Calkyl, C-Calkoxy. Additionally, R4 is H, halo, a substituted or unsubstituted group selected from C-Calkyl, C-Calkoxy, C-Ccycloalkyl, arylC-Calkyl and phenyl, or R3 and R4 are combined to form a C-Ccycloalkyl.

Peroxisome proliferator activated receptor alpha agonists

The present invention is directed to compounds represented by the following structural formula, and pharmaceutically acceptable salts, solvates and hydrates thereof, R1 is selected from the group consisting of hydrogen, substituted or unsubstituted group selected from C1&#x2013;C8 alkyl, aryl-C0-4-alkyl, heteroaryl-C0-4-alkyl, and C3&#x2013;C6 cycloalkylaryl-C0-2-alkyl; W is O or S; X is an optionally substituted C1&#x2013;C5 alkylene linker wherein one carbon atom of the linker may be replaced with O, NH or S; Y is C, O, S, NH or a single bond; E is C(R3)(R4)A or A 

The present invention is directed to N-acylated derivatives of desleucylA82846B. These derivatives are useful as antibacterials.

N1-modified glycopeptides

Disclosed are compounds which inhibit &#x3b2;-amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease. Also disclosed are pharmaceutical compositions that include a compound which inhibits &#x3b2;-amyloid peptide release and/or its synthesis as well as methods for treating Alzheimer's disease both prophylactically and therapeutically with such pharmaceutical compositions.

Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting &#x3b2;-amyloid peptide release and/or its synthesis by use of such compounds

Disclosed are compounds which inhibit &#x3b2;-amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease. Also disclosed are pharmaceutical compositions comprising a compound which inhibits &#x3b2;-amyloid peptide release and/or its synthesis as well as methods for treating Alzheimer's disease both prophylactically and therapeutically with such pharmaceutical compositions.

Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds

Disclosed are compounds which inhibit &bgr;-amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease. Also disclosed are pharmaceutical compositions comprising a compound which inhibits &bgr;-amyloid peptide release and/or its synthesis as well as methods for treating Alzheimer's disease both prophylactically and therapeutically with such pharmaceutical compositions.

Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting &bgr;-amyloid peptide release and/or its synthesis by use of such compounds

Described herein are N&prime;-acylated derivatives of desleucylA82846B. The compounds are useful as antibacterial agents.

N1 modified glycopeptides

Disclosed are compounds which inhibit &bgr;-amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease. Also disclosed are pharmaceutical compositions that include a compound which inhibits &bgr;-amyloid peptide release and/or its synthesis as well as methods for treating Alzheimer's disease both prophylactically and therapeutically with such pharmaceutical compositions.

Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting &bgr;-amyloid peptide release and/or its synthesis by use of such compounds

Disclosed are biological reagents which comprise compounds that inhibit &bgr;-amyloid peptide release and/or its synthesis, and, accordingly, have utility in determining the cellular mechanism involved in the generation of &bgr;-amyloid peptide.

Biological reagents and methods for determining the mechanism in the generation of &bgr;-amyloid peptide

Glycopeptide compounds

Growing community of inventors

Frankfort, IN, United States of America

Richard Craig Thompson